论文部分内容阅读
目的 探讨药物治疗小儿支原体肺炎的临床疗效?方法 选择朝阳县中心医院收治的小儿支原体肺炎患儿64例为研究对象，时间为2016年2月至2018年1月?随机分组，阿奇霉素治疗组采取阿奇霉素治疗，孟鲁司特钠联合阿奇霉素治疗组则采取孟鲁司特钠联合阿奇霉素治疗?比较效果?结果 孟鲁司特钠联合阿奇霉素治疗组疗效高于阿奇霉素治疗组，P0.05?与阿奇霉素治疗组相比，治疗“,”Objective To explore the clinical efficacy of drug therapy for children with mycoplasma pneumoniae pneumonia. Methods Sixty-four children with mycoplasma pneumonia from February 2016 to January 2018 were selected. Patients in the azithromycin treatment group received azithromycin， while those in the montelukast combined with azithromycin treatment group received azithromycin and montelukast. Comparison effect. Results The curative effect of montelukast combined with azithromycin treatment group was higher than that of azithromycin treatment group， P 0.05; compared with the azithromycin treatment group， after treatment with montelukast combined with azithromycin treatment group\'s the changes of inflammatory index C reactive protein， white blood cell count， lung function index vital capacity， forced expiratory volume in the first second and peak expiratory flow rate were more significant (P <0.05). Compared with the azithromycin treatment group， the time of disappearance of shortness of breath was shorter in montelukast combined with azithromycin treatment group (P 0.05.Conclusion Montelukast combined with azithromycin is effective in the treatment of children with mycoplasma pneumoniae pneumonia， which can control lung inflammation and improve lung function.